Amgen AMG 757 (Small Cell Lung Cancer)
What is the Purpose of this Study?
- Receive the study drug (tarlatamab) intravenously
- Provide tumor tissue
- Have physical exams, blood draws, and give urine samples
- Have imaging scans (CT and/or MRI)
- Have heart tests (ECG)
Who Can Participate in this Study?
- Are diagnosed with SCLC
- Did not respond to previous treatment or had their cancer return after treatment ended
For more information about who can join this study, please contact the study team at 919-681-6468.
What is Involved?
We are doing this study to find out if an experimental drug called tarlatamab is a safe and effective treatment for SCLC.
Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment